Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide + daratumumab + dexamethasone versus daratumumab + bortezomib + dexamethasone in relapsed or refractory multiple myeloma
NL-OMON54280Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Dec 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iberdomide in multiple myeloma (MM) (5 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Dec 2022; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54280.